BEAM-301 in GSDIa
Beam Therapeutics have put out a press release that includes an update on U.S. Food and Drug Administration clearance for their investigational new drug application for BEAM-301 in GSDIa.
A recent Beam press release reports on clearance by the U.S. Food and Drug Administration for their investigational new drug (IND) application for BEAM-301 in GSDIa.
Now that the FDA has cleared their application, Beam are working to open their Phase 1/ 2 trial in multiple US sites. Although the Phase 1/ 2 trial will be US only, they hope the program is successful so that in the future they may be able to expand outside of the US for a Phase 3 study.
You can read the press release below.
